# BME103:W930 Group1

(Difference between revisions)
Jump to: navigation, search
 Revision as of 16:40, 14 November 2012 (view source) (→Protocols)← Previous diff Revision as of 16:42, 14 November 2012 (view source) (→Results)Next diff → Line 201: Line 201: * '''Integrated Density''' = Integrated Density (INTDEN) is a measurement of the mean gray value for a specific area. The INTDEN values in the table were calculated by determining the INTDEN of the drop and subtracting it from the INTDEN of the background. * '''Integrated Density''' = Integrated Density (INTDEN) is a measurement of the mean gray value for a specific area. The INTDEN values in the table were calculated by determining the INTDEN of the drop and subtracting it from the INTDEN of the background. * '''DNA μg/mL''' = The concentration of DNA in each sample was calculated by multiplying each sample's INTDEN value by 2 and dividing by the INTDEN value of the calf thymus. * '''DNA μg/mL''' = The concentration of DNA in each sample was calculated by multiplying each sample's INTDEN value by 2 and dividing by the INTDEN value of the calf thymus. - * '''Conclusion''' = Each calculated DNA concentration was compared to the concentrations of both the negative and positive controls. The samples with concentrations less than the negative result produced no signal while the those with concentrations greater than the negative control produced a positive test for cancer. However, the DNA concentration for patient one was closer to the positive control while the DNA concentration for patient two is closer to (but still greater than) the positive control. The conclusion is that patient one most likely has cancer while patient two probably does not have cancer. + * '''Conclusion''' = Each calculated DNA concentration was compared to the concentrations of both the negative and positive controls. The samples with concentrations less than the negative result produced no signal while the those with concentrations greater than the negative control produced a positive test for cancer. However, the DNA concentration for patient one was closer to the positive control while the DNA concentration for patient two is closer to (but still greater than) the positive control. The conclusion is that patient one most likely has cancer while patient two probably does have cancer.

## Revision as of 16:42, 14 November 2012

BME 103 Fall 2012 Home
People
Lab Write-Up 1
Lab Write-Up 2
Lab Write-Up 3
Course Logistics For Instructors
Photos
Wiki Editing Help

# OUR TEAM

All members of the group participated within their respective roles and contributed to the content of this page. Bri Ackerman, Haley Parrott, and Michael Dennison did not have their accounts verified by the time this page was submitted, therefore their names will not show up in the editing history.

 Name: Kevin ChuExperimental Protocol Planner and Data Analyzer Name: Michael DennisonExperimental Protocol Planner Name: Zhiyue YangMachine Engineer Name: Vanessa BarkerMachine Engineer Name:Bri AckermanResearch and Development Scientist Name:Ben DuguayResearch and Development Scientist Name:Haley ParrottResearch and Development Scientist

# LAB 1 WRITE-UP

## Initial Machine Testing

The Original Design
This picture (click to enlarge) illustrates the original design of the Open PCR machine showing inner mechanisms. As the image shows, the Open PCR machine primarily consists of 5 parts: the LCD screen, heated lid, heater, circuit board, and fan. While the machine is portable and easy to use, the design is fragile and has a high failure rate, along with several other design flaws.

Experimenting With the Connections
When we unplugged the LCD screen from the circuit board, the machine's screen stopped displaying. When we unplugged the white wire that connects the circuit board to the heated lid, the temperature reported by the machine dropped, suggesting that the machine stopped controlling the temperature of the heated lid.

Test Run
Our group used machine #1. During our first test run on October 24, 2012, the PCR machine was connected to a laptop that contained the program for the thermal cycling process. All of the tubes containing the DNA samples were placed into the tray, which was then placed into the open PCR machine. During the amplification, the machine's fan was not functioning. Therefore, we could not complete the DNA replication. However, previously prepared DNA solutions were available, so we conducted the experiment with these samples instead.

## Protocols

Polymerase Chain Reaction
DNA is a useful health marker and can predict the likelihood that a patient has cancer, but the molecule is often available only in minute quantities. Polymerase chain reaction (PCR) is a process that amplifies minute quantities of DNA in order to obtain a sufficient number of samples for analysis. During PCR, the double helix structure is unzipped to expose the bases. DNA primer is added to the DNA solution and binds to the gene that causes cancer. An enzyme called Taq polymerase, originally found in thermophilic bacteria, catalyzes the extension of the synthetic DNA molecule. Because a non-cancer gene has a different nucleotide sequence from the cancer gene, the primer will not be able to attach to the exposed bases, so the DNA cannot be amplified. DNA amplification involves a sequence of steps called thermal cycling.

Thermal Cycling
1. First, the DNA solution was heated at 95°C for 30 seconds.
2. During denaturing, the temperature was held at a constant 95°C for an additional 30 seconds to break the hydrogen bonds between the complementary bases in the DNA molecules.
3. During annealing, the temperature was decreased to 55°C for 30 seconds to allow the specific primers to attach to the region of DNA encoding the cancer gene.
4. During extension, the temperature was increased to 72°C for one minute to allow Taq DNA polymerase to bind deoxynucleoside triphosphates (dNTPs) on the template DNA. Lengthening the synthetic strand.
5. The temperature was decreased to 20°C during the final hold.
6. To obtain a sufficient number of DNA samples, the entire process was repeated 30 times.

Components of the PCR master mix
• 2X Colorless Go Taq ® Reaction Buffer (pH 8.5)
• 400μM dATP
• 400μM dGTP
• 400μM dCTP
• 400μM dTTP
• 3mM MgCl2

Reagent and Volume of DNA Solution

 Reagent Volume Template DNA (20 ng) 0.1μL 10μM forward primer 0.5μL 10μM reverse primer 0.5μL GoTaq master mix 25.0μL dH2O 23.9μL Total Volume 50.0μL

Description of DNA Samples
Positive Control
Cancer DNA template

Patient 1
Replicate 1
ID: 92336
Gender: Male
Age: 58

Patient 1
Replicate 2
ID: 92336
Gender: Male
Age: 58

Patient 1
Replicate 3
ID: 92336
Gender: Male
Age: 58

Patient 2
Replicate 1
ID: 44606
Gender: Male
Age: 47

Patient 2
Replicate 2
ID: 44606
Gender: Male
Age: 47

Patient 2
Replicate 3
ID: 44606
Gender: Male
Age: 47

Flourimeter Measurements

Flourimeter Assembly and Experiment Procedure
1. The box was assembled by removing the lid and unbuttoning one of its sides.
2. Then, the box was placed upside down onto the lid, and the unbuttoned flap was lifted up. This created a dark environment that would allow for accurate measurements of the fluorescence of SYBR green dye.
3. Sample A was pipetted onto the slide. Because the slide is superhydrophobic, a drop formed on its surface.
4. Then, the slide was placed on the fluorimeter and adjusted so that the light fluoresced through the sample.
5. The superhydrophobic slide and its stand were placed near the back of the dark interior of the box.
6. The cell phone stand was placed near the front of the box, and the smartphone was placed on the stand.
7. Both the cell phone and the hydrophobic slide were aligned in the middle of the box. Neither the phone nor the fluorimeter was moved after adjusting them.
8. Then, using the camera function on the smartphone, the photograph was taken of the sample.
9. Steps 3-8 were repeated with the remaining DNA samples.

ImageJ Procedure
1. When each photograph was taken, it was automatically saved into the memory of the smartphone.
2. After all of the photographs were taken, all of the images were attached to an email and sent to a computer that operated the ImageJ program.
3. The email was received by the computer, and the file containing the image was downloaded by right-clicking on the file and opening with ImageJ.

## Research and Development

Specific Cancer Marker Detection - The Underlying Technology

The primer sequence of the single nucleotide polymorphism (SNP) that is linked to colorectal cancer is GGAAGTGGGTCCTAAAAACTCTTACA [C/T] TGCATACATAGAAGATCAGAGTGGC. The allele change is from T to C, meaning that when the T base pair mutates into a C base pair, the cancer sequence is expressed. The gene being affected in this mutation is checkpoint kinase 2 (CHK2). Detection of this gene mutation is achieved through a process called polymerase chain reaction (PCR), which is a technology that amplifies a single copy of DNA to generate a multitude of that specific sequence. This allows scientists and researches to isolate a specific DNA sequence in order to compare it to a specific phenotype, which in this case is the presence of colorectal cancer. The cancer sequence-binding primer, or the reverse primer, is AACTCTACA[C]TGCATACAT. The coordinate (location) of the cancer base pair "C" is at 29,121,087 of the DNA sequence. 20 base pairs to the left of the cancer sequence was TA, which occurred at coordinate 29,121,067.

Baye's reasoning and statistical formulas can be applied to find the link between the development of cancer and the presence of the cancer gene in the SNP. In a sample size of 180 patients, 1.1% of contained a single copy of the colorectal cancer (CRC) gene in their DNA (C/T) and 98.9% had no copy of the cancer gene (T/T). According to Baye's rule, when the probability of expressing the "C" gene and also having cancer is 7.8%:

The probability of having cancer and also expressing the "C" gene = 1.1%
The probability of having cancer with the "C" = 0.74%
The standard probability of having cancer over the population is 5.3%.

## Results

 Sample Integrated Density DNA μg/mL Conclusion PCR: Water 9647140 0.0000 No Signal PCR: Calf thymus DNA 54999590 2.0000 Positive PCR: Negative Control 6549794 0.2382 No Signal PCR: Positive Control 48651893 1.7692 Positive PCR: Patient 1 ID 92336, rep 1 42249825 1.5364 Positive PCR: Patient 1 ID 92336, rep 2 38240163 1.3906 Positive PCR: Patient 1 ID 92336, rep 3 65596983 2.3854 Positive PCR: Patient 2 ID 44606, rep 1 10866235 0.3951 Positive PCR: Patient 2 ID 44606, rep 2 16970600 0.6171 Positive PCR: Patient 2 ID 44606, rep 3 12971264 0.4717 Positive

KEY

• Sample = Each sample is a solution of amplified DNA obtained via PCR. The first four rows of the table display the water sample, calf thymus DNA, negative control and positive control. Rows 5-7 show results for 3 replicates of patient 1, and rows 8-10 show 3 replicates of patient 2.
• Integrated Density = Integrated Density (INTDEN) is a measurement of the mean gray value for a specific area. The INTDEN values in the table were calculated by determining the INTDEN of the drop and subtracting it from the INTDEN of the background.
• DNA μg/mL = The concentration of DNA in each sample was calculated by multiplying each sample's INTDEN value by 2 and dividing by the INTDEN value of the calf thymus.
• Conclusion = Each calculated DNA concentration was compared to the concentrations of both the negative and positive controls. The samples with concentrations less than the negative result produced no signal while the those with concentrations greater than the negative control produced a positive test for cancer. However, the DNA concentration for patient one was closer to the positive control while the DNA concentration for patient two is closer to (but still greater than) the positive control. The conclusion is that patient one most likely has cancer while patient two probably does have cancer.